Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.7K citations · Full text

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine · 2014 · 5.3K citations · Full text

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon et al. · The Lancet · 2020 · 2.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +5

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Javier Muñoz, André Goy et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

Donna Upchurch, SJ Szilvassy, ML Guzman et al. · Leukemia · 2000 · 808 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +12